Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Q3 2021 Earnings Presentation
20 slides from Evofem Biosciences's earnings presentation, Nov 15, 2021
Slide 1: Third Quarter 2021 Results Call
Revolutionizing Women’s Sexual and Reproductive Health Third Quarter 2021 Results Call November 15, 2021 NASDAQ: EVFM evofem.com © 2021 Evofem Biosciences, Inc. | For investor discussions only.
Slide 2: Forward-Looking Statements
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 2 Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify for
Slide 3: Strong TRx Growth Continues
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 3 Strong TRx Growth Continues 48% TRx INCREASE Q3 VS. Q2 27% MONTHLY TRx INCREASE FROM SEPT TO OCT 2021* 0 5,000 10,000 15,000 20,000 25,000 Q1 2021 Q2 2021 Q3 2021 0 2,500 5,000 7,500 10,000 12,500 Aug. 2021 Sept. 2021 Oct. 202
Slide 4: Q3 2021 Financial Results + Expected OpEx Reductions
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 4 Q3 2021 Financial Results + Expected OpEx Reductions Gross revenues grew 29% Q3 vs. Q2 Net product sales: $1.7M Operating expenses: $45.1 million • R&D: $8.7 million - Phase 3 STI prevention trial • Selling & marketing: $30.5
Slide 5: Balance Sheet Highlights
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 5 Balance Sheet Highlights $23.9 M for use in ongoing operations as of September 30, 2021 • $14.9 M cash and cash equivalents • $ 9.0 M restricted cash from the Adjuvant notes $10 M raised in October 2021 • Runway into Q1 2022
Slide 6: Leading the Contraception Revolution
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 6 Leading the Contraception Revolution
Slide 7: Strong Quarter over Quarter Growth: Phexxi Prescriber Base
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 7 Strong Quarter over Quarter Growth: Phexxi Prescriber Base 1,709 2,678 2,767 2,827 4,407 7,168 9,994 - 2,500 5,000 7,500 10,000 12,500 4Q 20 1Q21 2Q 21 3Q 21 First Time Writers Total Writers (cum.) MORE THAN 2,800 HEALTHCARE P
Slide 8: Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 8 Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units 0 5,000 10,000 15,000 20,000 25,000 4Q20 1Q21 2Q21 3Q21 Total Rx Units Source(s): • XPO Dispensed Units & TRx from Pharmacy (including Knipper) • 340b/VA da
Slide 9: Increasing Brand Awareness
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 9 Increasing Brand Awareness Source: Phoenix PatientView Consumer Birth Control Tracker PHEXXI TOTAL BRAND AWARENESS HIT 19% IN OCTOBER 2021 0% 5% 10% 15% 20% 25% Jan Feb Mar Apr May Jun Jul Aug Sept Oct DTC Launch 2/14/21 Celeb
Slide 10: Dramatic Growth After "House Rules" Launch
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 10 - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 New Rx Total Rx Units 6 weeks pre-HR 6 weeks post-HR Dramatic Growth After “House Rules” Launch 82% 6 weeks pre-House Rules includes weeks ending 8/6/21 to 9/10/21
Slide 11: ACA Strategy – Two Paths, Both a Win for Phexxi
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 11 ACA Strategy – Two Paths, Both a Win for Phexxi Goal: Guide revised to include new Vaginal pH Modulator category Update the Office of Women’s Health birth control guide Goal: Prevent OWH birth control guide from being used to
Slide 12: ACA Strategy 1: Update the OWH Birth Control Guide
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 12 ACA Strategy 1: Update the OWH Birth Control Guide Goal: Guide revised to include new Vaginal pH Modulator category Update the Office of Women’s Health birth control guide Goal: Prevent OWH birth control guide from being used
Slide 13: Petition to Demonstrate Consumer Demand for Equal Contraceptive Rights and Coverage
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 13 Petition to Demonstrate Consumer Demand for Equal Contraceptive Rights and Coverage ACHIEVED OVER 12,000 SIGNATURES IN JUST 8 WEEKS GOAL = 20,000 BY THANKSGIVING JOIN THE MOVEMENT SCAN ME NOW! Signatures from September 17 – N
Slide 14: ACA Strategy 2: Update Guidance from HRSA
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 14 ACA Strategy 2: Update Guidance from HRSA Goal: Guide revised to include new Vaginal pH Modulator category Update the Office of Women’s Health birth control guide Goal: Prevent OWH birth control guide from being used to limit
Slide 15: R&D: Prevention of Chlamydia & Gonorrhea
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 15 R&D: Prevention of Chlamydia & Gonorrhea 1. US Centers for Disease Control and Prevention (2019): CDC detailed fact sheet on gonorrhea and CDC detailed fact sheet on chlamydia 2. Daniels K, Abma JC. Current contraceptive stat
Slide 16: R&D: Timeline - Prevention of Chlamydia & Gonorrhea
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 16 R&D: Timeline - Prevention of Chlamydia & Gonorrhea Fast Track Review 2021 2022 2023 2024 Potential U.S. Approval & Commercial Launch3 sNDA Submission2Top-Line Results1 Complete Enrollment1 1. Assumes timely enrollment 2. Ass
Slide 17: Additional Value Creating Opportunities
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 17 Additional Value Creating Opportunities U.S.: leverage sales force • Detail synergistic product to OB/GYNs and allied HCPs • Offset sales force cost Outside U.S. • Secure partnership(s) for commercialization of Phexxi • Discu
Slide 18: Questions
Questions E“OFEM BOL OF SiG TEIN (Goaes®
Slide 19: Executing Our Key Initiatives
© 2021 Evofem Biosciences, Inc. | For investor discussions only. Page | 19 Executing Our Key Initiatives Reduce operating expenses by ~$50 million in 2022 Increase access to Phexxi by spurring an update to the OWH chart or HRSA guidance Drive our STI prevention program forward Enter licensing agreem
Slide 20: 1.858.550.1900 ir@evofem.com 12400 High Bluff Drive, Suite 00 San Diego, California 92130 evofem.com
1.858.550.1900 ir@evofem.com 12400 High Bluff Drive, Suite 600 San Diego, California 92130 NASDAQ: EVFM evofem.com